Treatment of Local Skin Hypotrophy Conditions

A method of treating at least one local skin hypotrophy condition and/or of cosmetic care for aging skin comprising:

• obtaining fibroblast growth factor (FGF) messenger-RNA (mRNA), wherein the mRNA has a 5′ CAP region, a 5′ untranslated region (5′-UTR), a coding region encoding human FGF, a 3′ untranslated region (3′-UTR) and a poly-adenosine Tail (poly-A tail) wherein:
• the coding region of the FGF mRNA encodes for human fibroblast growth factor 2 (FGF2);
• or
• the coding region of the FGF mRNA encodes for human fibroblast growth factor 7 (FGF7);
• and
• administering the FGF mRNA to a subject having a local skin hypertrophy condition and/or aging skin;
• wherein the local skin hypotrophy condition and/or aging skin is treated in the subject.

A fibroblast growth factor (FGF) messenger-RNA (mRNA), wherein the mRNA has a 5′ CAP region, a 5′ untranslated region (5′-UTR), a coding region encoding human FGF, a 3′ untranslated region (3′-UTR) and a poly-adenosine Tail (poly-A tail);

• wherein:
• the coding region of the FGF mRNA encodes for human fibroblast growth factor 2 (FGF2);
• or
• the coding region of the FGF mRNA encodes for human fibroblast growth factor 7 (FGF7).

A method of producing a pharmaceutical composition comprising:

• obtaining a fibroblast growth factor (FGF) messenger-RNA (mRNA), wherein the mRNA has a 5′ CAP region, a 5′ untranslated region (5′-UTR), a coding region encoding human FGF, a 3′ untranslated region (3′-UTR) and a poly-adenosine Tail (poly-A tail);
• wherein:
• the coding region of the FGF mRNA encodes for human fibroblast growth factor 2 (FGF2);
• or
• the coding region of the FGF mRNA encodes for human fibroblast growth factor 7 (FGF7):
• and
• formulating the FGF2 or FGF7 mRNA with at least one pharmaceutically acceptable carrier.